#GateIPOAccessAnthropic The grey market is already up 33%, and the golden buying opportunity closed five weeks ago

This IPO is neither a golden buying opportunity nor a chance to escape. The grey market is already up 33%, and the golden buying opportunity closed five weeks ago! This is “a high-valuation growth stock offering that was priced in ahead of time.” The line between a bargain and an opportunity isn’t the company—it’s the price.

I. Look at the market, not just the prospectus

The prospectus says: 825 million shares, $70 to $78, a fully diluted valuation of $1.26 trillion to $1.41 trillion, pricing on November 18, trading on the 19th, and ticker ANT.

But the market is already ahead of it: subscription orders have reached several times the shares on offer, underwriters are considering pushing the valuation above $1.5 trillion, and the final offer price could exceed the $78 upper limit.

The grey market makes this even clearer. The xyz:ANT contract, which settles against the IPO price, is already trading at $103.91, about 33% above the $78 upper limit, implying a diluted valuation of about $1.91 trillion. Some institutions that received allocations early are already transferring existing shares through SPVs.

There’s another bit of context: five weeks ago, the valuation high being discussed by the market was $2 trillion; now it’s been cut straight to $1.4 trillion. This “halving of expectations” is itself a textbook case of expectation management.

II. How to tell “bargain or escape”

First, is there still a discount?

The purpose of the pricing range is to give primary-market buyers a margin of safety. The grey market is now already 33% above the upper limit, so that margin of safety is gone. If you get an allocation, you’re buying at the “offer price,” but the grey-market price is the reference for the first day of trading—the gap has already been pocketed by someone else.

Second, who’s selling?

Of the 825 million shares this time, the company itself is issuing about 801 million, while existing shareholders are selling only about 23.65 million; the seven founders are also cashing out about $1.8 billion in total. Against total proceeds of $90.4 billion, the cash-out accounts for only around 2%.

So this isn’t a “mass escape.” Most of the money is going into the company’s coffers to fund computing capacity—it now has close to $900 billion in computing expenditure commitments. This is additional funding for expansion, not shareholders selling out and leaving.

Third, is there still a case for calling the valuation cheap?

At a fully diluted valuation of $1.4 trillion and annualized third-quarter revenue of about $68 billion, the price-to-sales ratio is 20.7x; compared with OpenAI’s $1.25 trillion valuation on $50 billion in annualized revenue, or 25x, ANT is about 20% cheaper.

But at the grey-market valuation of $1.91 trillion, the price-to-sales ratio is 28x, making it more expensive than OpenAI.

So the “relatively cheap” argument holds only within the $70 to $78 range. Once the price moves higher, the discount disappears. That’s why I think the final price will most likely land at $80 to $85—any higher, and applying for shares is no longer worthwhile.

III. Three players, three different answers

For the company: this is a chance to raise funds—$90.4 billion, surpassing SpaceX to become the largest public listing in history, with the money going toward building computing capacity.

For the founders and early shareholders: this is a chance to exit and cash out—with $1.8 billion cashed out and existing shares transferred through SPVs, selling in this round at a valuation of $1.9 trillion is already a very good deal.

For retail investors: this is a lottery ticket with low allocation odds, a possible increase in the offer price, and a first-day premium already reflected in the grey market. The risk-reward is worse than it was five weeks ago, and perhaps even worse than waiting for a pullback after the listing.

IV. If you must participate, here’s what I’d do

First, price. Participate only in the lower part of the range ($70 to $73); if the final price exceeds $85, I’ll walk away—that would put the price-to-sales ratio above 24x, making it less attractive than buying from its shareholders.

Second, position size. No more than 5% of total assets; treat it as an event-driven trade, not a long-term holding.

Third, timing. If it rises more than 30% on the first day, sell half; if it falls 10% below the offer price, don’t add; around May 2027 is when the six-month lockup expires, and I’d reduce the position to zero before then.

V. The real risk isn’t that it’s “expensive”

Third-quarter revenue was $16.956 billion, up about 12x year over year and 47% quarter over quarter; in the same period, the GAAP net loss was $23.3 billion. The company says this includes large non-cash items related to preferred shares—so you can’t simply say it “burned $23.3 billion in cash.” But the close to $900 billion in computing commitments is real.

This means the company will have to keep raising funds over the coming years. If capital markets tighten up on AI, it will become “the most expensive capital-intensive company in the market.” This isn’t a valuation issue; it’s a cash flow issue.

So I’ll be watching two numbers: whether gross margin can hold in the mid-60% range (API is currently above 80%), and whether revenue can maintain quarter-over-quarter growth above 30%. A decline in either of these numbers would be the real signal.

Would you apply for shares, or wait for it to fall 30% after listing before considering it? Tell me in the comments.